BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31981965)

  • 1. Structure-based discovery of novel inhibitors of Mycobacterium tuberculosis CYP121 from Indonesian natural products.
    Prasasty VD; Cindana S; Ivan FX; Zahroh H; Sinaga E
    Comput Biol Chem; 2020 Apr; 85():107205. PubMed ID: 31981965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
    Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
    Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical Screening of a Focused Library for the Discovery of CYP121 Inhibitors as Novel Antimycobacterials.
    Brengel C; Thomann A; Schifrin A; Allegretta G; Kamal AAM; Haupenthal J; Schnorr I; Cho SH; Franzblau SG; Empting M; Eberhard J; Hartmann RW
    ChemMedChem; 2017 Oct; 12(19):1616-1626. PubMed ID: 28815923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors.
    Walter I; Adam S; Gentilini MV; Kany AM; Brengel C; Thomann A; Sparwasser T; Köhnke J; Hartmann RW
    ChemMedChem; 2021 Sep; 16(18):2786-2801. PubMed ID: 34010508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylated Flavonoid Compounds as Potent CYP121 Inhibitors of
    Bajrai LH; Khateb AM; Alawi MM; Felemban HR; Sindi AA; Dwivedi VD; Azhar EI
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
    Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
    Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors.
    Kavanagh ME; Gray JL; Gilbert SH; Coyne AG; McLean KJ; Davis HJ; Munro AW; Abell C
    ChemMedChem; 2016 Sep; 11(17):1924-35. PubMed ID: 27432475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H; Suh JW
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.
    Saxena AK; Singh A
    Curr Top Med Chem; 2019; 19(5):337-355. PubMed ID: 30806318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis.
    Prabu A; Hassan S; Prabuseenivasan ; Shainaba AS; Hanna LE; Kumar V
    J Mol Graph Model; 2015 Sep; 61():133-40. PubMed ID: 26245695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
    Ganihigama DU; Sureram S; Sangher S; Hongmanee P; Aree T; Mahidol C; Ruchirawat S; Kittakoop P
    Eur J Med Chem; 2015 Jan; 89():1-12. PubMed ID: 25462220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.